within Pharmacolibrary.Drugs.ATC.A;

model A03AX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03AX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pinaverium is a musculotropic spasmolytic agent used to treat symptoms of irritable bowel syndrome and other gastrointestinal disorders. It acts mainly by inhibiting calcium influx into smooth muscle cells, reducing intestinal motility and spasms. It is approved in several countries but not globally available; not approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults after oral administration, as no publication with explicit PK parameters could be identified.</p><h4>References</h4><ol><li><p>Patiño-Rodríguez, O, et al., &amp; Pérez-Urizar, J (2015). Determination of Pinaverium Bromide in Human Plasma by a Sensitive and Robust UPLC-MS-MS Method and Application to a Pharmacokinetic Study in Mexican Subjects. <i>Journal of chromatographic science</i> 53(8) 1373–1378. DOI:<a href=\"https://doi.org/10.1093/chromsci/bmv027\">10.1093/chromsci/bmv027</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25862744/\">https://pubmed.ncbi.nlm.nih.gov/25862744</a></p></li><li><p>Ren, JM, et al., &amp; Zhang, ZQ (2011). A sensitive and specific liquid chromatography/tandem mass spectrometry method for determination of pinaverium bromide in human plasma: application to a pharmacokinetic study in healthy volunteers. <i>Biomedical chromatography : BMC</i> 25(12) 1369–1373. DOI:<a href=\"https://doi.org/10.1002/bmc.1611\">10.1002/bmc.1611</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21308709/\">https://pubmed.ncbi.nlm.nih.gov/21308709</a></p></li><li><p>Arısoy, M, et al., &amp; Doğan Kurtoğlu, E (2022). A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets. <i>Journal of pharmaceutical sciences</i> 111(11) 3149–3154. DOI:<a href=\"https://doi.org/10.1016/j.xphs.2022.08.010\">10.1016/j.xphs.2022.08.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35981633/\">https://pubmed.ncbi.nlm.nih.gov/35981633</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03AX04;
